» Articles » PMID: 26285910

Endovascular Management of Refractory Hepatic Encephalopathy Complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm

Overview
Date 2015 Aug 20
PMID 26285910
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) has evolved as an effective intervention for treatment of complications of portal hypertension. The use of polytetrafluoroethylene-covered stents have improved the patency of the shunts and diminished the incidence of TIPS dysfunction. However, TIPS-related refractory hepatic encephalopathy (rHE) poses a significant challenge. Approximately 3-7 % of patients with TIPS develop rHE. Refractory hepatic encephalopathy is defined as a recurrent or persistent encephalopathy despite appropriate medical treatment. Hepatic encephalopathy can be an extremely debilitating complication that profoundly affects quality of life. The approach to management of patients with rHE is complex and typically requires collaboration between different specialties. Liver transplantation is the ultimate treatment for rHE; however, the ongoing shortage of organ donation markedly limits this treatment option. Alternative therapies such as shunt occlusion or reduction can control symptoms and serve as a 'bridge' therapy to liver transplantation. Therefore, interventional radiologists play a key role in the management of these patients by offering a variety of endovascular techniques. The purpose of this review is to highlight some of these endovascular techniques and to develop a therapeutic algorithm that can be applied in clinical practice for the management of rHE.

Citing Articles

Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertion.

Tiede A, Stockhoff L, Ehrenbauer A, Rieland H, Cornberg M, Meyer B Metab Brain Dis. 2024; 40(1):58.

PMID: 39656322 PMC: 11632008. DOI: 10.1007/s11011-024-01436-2.


Utilizing a suture-constrained covered stent for shunt reduction to treat transjugular intrahepatic portosystemic shunt-related refractory hepatic encephalopathy: a retrospective study.

Mu M, Zhou T, Guo H, Fu X, Chen Z, Jiang W Jpn J Radiol. 2024; 42(11):1298-1304.

PMID: 38922569 DOI: 10.1007/s11604-024-01618-z.


Prophylaxis of hepatic encephalopathy: current and future drug targets.

Maharshi S, Sharma B Hepatol Int. 2024; 18(4):1096-1109.

PMID: 38492132 DOI: 10.1007/s12072-024-10647-9.


Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt.

Wang L, Yao X, Qi Q, Qin J World J Gastrointest Surg. 2023; 15(8):1564-1573.

PMID: 37701697 PMC: 10494578. DOI: 10.4240/wjgs.v15.i8.1564.


Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Cannella R, Tselikas L, Douane F, Cauchy F, Rautou P, Duran R JHEP Rep. 2022; 4(7):100484.

PMID: 35677591 PMC: 9168703. DOI: 10.1016/j.jhepr.2022.100484.